All studies
RecruitingTherapeutic exploratory (Phase II)Interventional

Nivolumab plus Ipilimumab plus two cycles of platinum-based chemotherapy as first line treatment for stage IV/recurrent non-small cell lung cancer (NSCLC) patients with synchronous Brain metastases_NIVIPI-Brain

When non-small cell lung cancer spreads to the brain, finding treatments that reach and control tumours in both the lungs and the brain can be challenging. This Phase II clinical trial looks at whether combining two immunotherapy drugs, called nivolumab (Opdivo) and ipilimumab (Yervoy), alongside two initial cycles of standard chemotherapy, is an effective first treatment. Immunotherapy works by helping your own immune system recognize and attack cancer cells. Chemotherapy directly damages fast-growing cancer cells. The main goal of this study is to find out if this drug combination stops brain tumours from growing or worsening for at least six months. The researchers also want to learn how well the treatment shrinks tumours throughout the rest of the body, how long the benefits last, and how it affects everyday quality of life.

At a glance

Status
Recruiting
Phase
Therapeutic exploratory (Phase II)
Sponsor
Fundacion GECP
Enrolment target
71
Start
24 May 2024

What is this study about?

Lung cancer is one of the most common cancers worldwide. In advanced non-small cell lung cancer (stage IV), cancer cells can spread from the lungs to other areas of the body, frequently including the brain. When brain tumours are present right from diagnosis, treating them effectively is critical. Many standard medicines struggle to reach tumours inside the brain due to the body's natural protective barriers, meaning new and better treatment options are urgently needed.

This study tests a treatment plan that brings together immunotherapy and chemotherapy. Immunotherapy medicines do not attack cancer cells directly; instead, they 'take the brakes off' your body's immune system so your white blood cells can seek out and destroy cancer cells. This trial uses two different immunotherapy drugs, nivolumab and ipilimumab, which work in slightly different ways to boost the immune response.

Alongside immunotherapy, participants also receive two cycles of standard chemotherapy at the start. Chemotherapy quickly damages cancer cells and may help kick-start the immune system's response. By combining these treatments early on, doctors hope to achieve quicker, stronger, and longer-lasting control of cancer both in the brain and across the whole body.

By gathering detailed information from this trial, doctors hope to improve overall survival and protect mental and physical functioning for people facing advanced lung cancer. Understanding how this combination works will help guide the best standard of care for future patients.

Key takeaways

  • Tests a combination of two immunotherapy medicines (nivolumab and ipilimumab) plus two cycles of chemotherapy.
  • Aimed at adults newly diagnosed with advanced non-small cell lung cancer that has spread to the brain.
  • The primary goal is keeping brain tumours stable or shrinking for at least six months.
  • Treatments are given as hospital drips alongside regular brain and body scans.
  • Participation is entirely voluntary and you can stop at any point.

Who may be eligible?

This trial is designed for adults aged 18 and older who have been diagnosed with advanced (stage IV) or recurrent non-small cell lung cancer. To be eligible, the cancer must have already spread to the brain at the time of diagnosis, meaning the brain tumours and lung cancer are discovered together.

Because this is being studied as a first-line treatment, participants generally cannot have had prior drug treatment for their advanced lung cancer. The trial is open to people of all genders.

Not everyone will be able to join. Factors such as your overall general fitness, past medical treatments, and the presence of certain other health conditions (like serious autoimmune disorders) will determine whether this combination is safe for you. Your hospital oncology team can review your medical records to confirm if you meet all necessary criteria.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I have been diagnosed with advanced (stage IV) or recurrent non-small cell lung cancer.
  3. My cancer has spread to my brain (brain metastases).
  4. I have not yet started systemic drug treatment for this advanced cancer stage.
  5. I am well enough to attend regular hospital appointments for infusions and scans.
Answer every question to see your result.

What does participation involve?

Taking part involves receiving medications through a small tube into a vein (an intravenous infusion or 'drip') at a hospital day clinic. You would receive the two immunotherapy drugs (nivolumab and ipilimumab) on a regular schedule, together with two cycles of chemotherapy given over the first few weeks of treatment. A typical hospital visit involves blood tests, checks with your clinical team, and time in the clinic to receive your medicines.

Throughout the study, you will have regular medical imaging, including brain MRI scans and chest CT scans. These scans allow doctors to track how your tumours are responding to treatment. You will also be asked to complete short questionnaires to measure your day-to-day well-being and quality of life.

Your participation continues as long as the treatment is helping you and the side effects remain manageable. Follow-up appointments will continue for up to two years or longer to monitor your long-term health, even after active drug treatment finishes.

Potential risks and benefits

The potential benefit of taking part is receiving a combination of advanced treatments that may shrink tumours or stop them from growing in both your brain and lungs. However, there is no guarantee that this treatment will work for every participant. The combination carries risks of side effects. Chemotherapy commonly causes tiredness, nausea, loss of appetite, and an increased risk of infections. Immunotherapy can cause the immune system to attack healthy tissues, leading to inflammation in organs such as the skin, bowels, liver, or lungs. Your medical team will monitor you very closely and can prescribe medicines like steroids to manage these reactions. Taking part is completely voluntary, and you can choose to leave the trial at any time without it affecting your standard NHS care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Spain

Common questions

What is the difference between immunotherapy and chemotherapy?

Chemotherapy works by directly killing fast-growing cancer cells, while immunotherapy trains your body's own immune system to recognize and attack the cancer.

Do I have to pay to take part in this clinical trial?

No. In the UK, clinical trial medications and study-related tests are provided free of charge, and you continue to receive standard NHS support.

Will this cure my cancer?

Stage IV lung cancer that has spread to the brain is generally not considered curable. The aim of this treatment is to control the cancer, help you live longer, and preserve your quality of life.

How often will I need to have brain scans?

You will have regular scans (usually MRI scans of the brain and CT scans of the body) every few weeks or months to see if the tumours are shrinking or staying stable.

Can I leave the trial if I change my mind?

Yes. You have the right to withdraw from the study at any time, for any reason, without giving an explanation. Your medical team will ensure you switch to the best available alternative treatment.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "Nivolumab plus Ipilimumab plus two cycles of platinum-based …" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.